Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 16/20 | 0.83 |
| ▸ | PPARG | P37231 | 3/20 | 0.80 |
| ▸ | PPARA | Q07869 | 2/20 | 0.80 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.80 |
| ▸ | PTGES | O14684 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Delta-Tocotrienol SCHEMBL16430161 | 1.00 | ALOX5 (0.83) | ALOX5PPARGPPARANR1I2PTGES | |
| Delta-Tocotrienol SCHEMBL29719268 | 1.00 | ALOX5 (0.83) | ALOX5PPARGPPARANR1I2PTGES | |
| Delta-Tocotrienol SCHEMBL4648783 | 1.00 | ALOX5 (0.83) | ALOX5PPARGPPARANR1I2PTGES | |
| Delta-Tocotrienol SCHEMBL8408117 | 1.00 | ALOX5 (0.83) | ALOX5PPARGPPARANR1I2PTGES | |
| SCHEMBL18584115 | 0.93 | ALOX5 (0.88) | ALOX5PPARGPPARANR1I2PTGES | |
| SCHEMBL18584117 | 0.93 | ALOX5 (0.88) | ALOX5PPARGPPARANR1I2PTGES | |
| SCHEMBL18584016 | 0.91 | ALOX5 (1.00) | ALOX5PPARGPPARANR1I2PTGES | |
| SCHEMBL18583924 | 0.91 | ALOX5 (1.00) | ALOX5PPARGPPARANR1I2PTGES | |
| SCHEMBL16589603 | 0.90 | ALOX5 (0.68) | ALOX5PPARGPPARANR1I2PTGES | |
| SCHEMBL29974217 | 0.90 | ALOX5 (0.79) | ALOX5PPARGPPARANR1I2PTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11202814-B2 | Compositions for atopic skin | INFINITEC ACTIVOS, S.L. (ES) | 2021-12-21 | — | — | US | disclosed |
| US-20190240271-A1 | COMPOSITIONS FOR ATOPIC SKIN | INFINITEC ACTIVOS, S.L. (ES) | 2019-08-08 | — | — | US | disclosed |
| EP-3520774-A1 | COMPOSITIONS FOR ATOPIC SKIN | Infinitec Activos S.L. (ES) | 2019-08-07 | — | — | EP | disclosed |
| EP-3348253-B1 | LOW-ALCOHOL ORAL CARE COMPOSITIONS COMPRISING ETHYL LAUROYL ARGINATE | LACER SA (ES) | 2019-07-17 | — | — | EP | disclosed |
| EP-3348253-A1 | LOW-ALCOHOL ORAL CARE COMPOSITIONS COMPRISING ETHYL LAUROYL ARGINATE | Lacer, S.A. (ES) | 2018-07-18 | — | — | EP | disclosed |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECHNOLOGY CORPORATION | 2016-11-10 | — | — | US | disclosed |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS INC. | 2013-10-10 | — | — | US | disclosed |
| EP-1044687-B1 | POWDERS CONTAINING TOCOTRIENOLS AND TABLETS PREPARED BY COMPRESSION MOLDING THE SAME | FUJI CHEM IND CO LTD (JP) | 2008-09-03 | — | — | EP | disclosed |
| US-7074825-B2 | Composition and method for treating cancer | MO HUANBIAO | 2006-07-11 | — | — | US | disclosed |
| WO-2005032544-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | EDISON PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | disclosed |
| US-20040176311-A1 | Composition and method for treating cancer | MO HUANBIAO (US) | 2004-09-09 | — | — | US | disclosed |
| US-20040110848-A1 | Method and kit for treating cancer | PEFFLEY DENNIS M | 2004-06-10 | — | — | US | disclosed |
| US-6441029-B1 | D-.GAMMA.-TOCOTRIENOL, 2-DESMETHYLTOCOTRIENOL, D-.DELTA.-TOCOTRIENOL OR D-TOCOTRIENOL AND LOVASTATIN | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2002-08-27 | — | — | US | disclosed |
| EP-1044687-A1 | POWDERS CONTAINING TOCOTRIENOLS, PROCESS FOR PRODUCING THE SAME AND TABLETS PREPARED BY COMPRESSION MOLDING THE SAME | FUJI CHEMICAL INDUSTRY CO., LTD. (JP) | 2000-10-18 | — | — | EP | disclosed |
| US-6133312-A | ORALLY ADMINISTERING A SYNERGISTIC TOCOTRIENOL AND IONONE MIXTURE TO INHIBIT TUMOR GROWTH | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2000-10-17 | — | — | US | disclosed |
| US-6056940-A | TECHNETIUM-99M COMPLEXING MOIETY COVALENTLY LINKED TO A PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR BINDING MOIETY HAVING A MOLECULAR WEIGHT OF LESS THAN 10,000 DALTONS | DIATIDE, INC. (US) | 2000-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | CLN6, LDHA, NLN | ALOX5 1992/4885PPARG 2137/4885PPARA 1090/4885 |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | ALOX5 1604/4885PPARG 1252/4885PPARA 917/4885 |
| US-11202814-B2 | Compositions for atopic skin | PNN, TSLP, CUTA | ALOX5 47/4885PPARG 1357/4885PPARA 1146/4885 |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | ALOX5 1604/4885PPARG 1252/4885PPARA 917/4885 |
| US-20190240271-A1 | COMPOSITIONS FOR ATOPIC SKIN | PNN, TSLP, CUTA | ALOX5 47/4885PPARG 1357/4885PPARA 1146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.